A Model of the Cost Effectiveness of Infliximab for the Treatment of Severely Active Ulcerative Colitis, in Children and Adolescents Aged 6 to 17 Years, Who Have Had an Inadequate Response to Conventional Therapy
Abstract
Authors
J. Farrell Y. Jiang M.A. Chaudhary O. Sheppard T. Gathany T. Fan